Nouvelle perspective de traitement dans le cancer bronchique non à petites cellules (CBNPC). Place de l'afatinib: Un inhibiteur oral et irréversible de la famille ErbB
Translated title of the contribution
:
A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker
Marie Wislez, David Malka, Jaafar Bennouna, Laurent Mortier, René Jean Bensadoun, Jér̂ome Sicard, Pascale Dielenseger, Jean Baptiste Rey, Denis Moro-Sibilot, Florian Scotté
Research output: Contribution to journal › Article › peer-review
4Scopus
citations
Fingerprint
Dive into the research topics of 'A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker'. Together they form a unique fingerprint.